Scripps La Jolla Nationally Recognized for Diabetes & Heart Care

Scripps Memorial Hospital La Jolla was recognized as a top hospital in the nation for both cardiac care and the treatment of diabetes by U.S. News & World Report. The magazine’s latest edition is devoted to outstanding health care across the nation and selected Scripps La Jolla as one of “America’s Best Hospitals.”

Out of 5,189 hospitals, only 3 percent are ranked in one of more of the 16 specialties in the 17th annual edition of the magazine’s “America’s Best Hospitals.” This is the second time that Scripps La Jolla has been recognized by the magazine as a national leader in cardiac care.

“This outstanding honor bestowed on Scripps La Jolla exemplifies the excellent care provided at our facility,” said Scripps La Jolla Chief Executive Gary Fybel. “We owe these accolades to the incredible dedication and talents of our hospital staff and physicians.”

The esteemed ranking in cardiac care by U.S.News & World Report comes on the heels of a recent announcement by Scripps Health to build a comprehensive Cardiovascular Institute as part of the $360 million first phase replacement of Scripps Memorial Hospital La Jolla. The institute will include the cardiac programs of Scripps Clinic/Scripps Green Hospital and Scripps La Jolla, and will be a center for the most advanced diagnostic and treatment options for patients with cardiovascular diseases, as well as serve as a center for medical research, clinical trials and graduate medical education.

In addition to receiving national recognition for its cardiac program, the hospital – home to The Whittier Institute for Diabetes, a subsidiary of Scripps Health – was ranked 20th in the nation in the “Endocrinology” category.

“In a struggle to overcome the diabetes epidemic facing 18 million Americans, few institutions such as The Whittier Institute for Diabetes have risen above all others in their total dedication,” says Chris Van Gorder, Scripps Health CEO and president. “Being recognized by U.S.News & World Report is confirmation that we are leading the way in innovative diabetes research, education, and patient care.”